Identification and characterization of an oxidative degradation product of fexofenadine, development and validation of a stability-indicating RP-UPLC method for the estimation of process related impurities and degradation products of fexofenadine in pharmaceutical formulations

Scientia Pharmaceutica

Volumn 80, Issue 2, 2012, Pages 295-309

  Vaghela, Bhupendrasinh ^a,b   Rao, Surendra Singh ^b   Reddy, Annarapu Malleshwar ^a   Venkatesh, Panuganti ^a   Kumar, Navneet ^a  

^a DR REDDY'S LABORATORIES LTD   (India)

^b Department of Computer Science and Engineering   (India)

Author keywords

Characterization; Fexofenadine; Forced degradation; Identification; Stability indicating; UPLC; Validation

Indexed keywords

ACETONITRILE; ACID; BASE; FEXOFENADINE; N OXIDE 2 [4 [1 HYDROXY 4 [4 [HYDROXY(DIPHENYL)METHYL] 1 OXIDO PIPERIDIN 1 YL]BUTYL]PHENYL] 2 METHYLPROPANOIC ACID; PHOSPHORIC ACID; PROPIONIC ACID DERIVATIVE; TRIETHYLAMINE; UNCLASSIFIED DRUG; WATER;

ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; DRUG DEGRADATION; DRUG IMPURITY; ELECTROSPRAY MASS SPECTROMETRY; FLOW RATE; OXIDATION; OXIDATIVE STRESS; PH; PHOTOLYSIS; PROTON NUCLEAR MAGNETIC RESONANCE; REVERSED PHASE LIQUID CHROMATOGRAPHY; TEMPERATURE; THERMAL EXPOSURE; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

EID: 84865109148     PISSN: 00368709     EISSN: 22180532     Source Type: Journal    
DOI: 10.3797/scipharm.1111-07     Document Type: Article

References (19)

1. The Merck Index, an encyclopedia of chemicals, drugs and biologicals. Merck & Co., Inc., Whitehouse Station, NJ, 2001.
2. Simpson K, Jarvis B. Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. Drugs. 2000; 59: 301-321. http://dx.doi.org/10.2165/00003495-200059020-00020
3. Oliveira DC, Weigch A, Rolim C M. Simple and reliable HPLC analysis of fexofenadine hydrochloride in tablets and its application to dissolution studies. Pharmazie. 2007; 62: 96-100. http://dx.doi.org/10.1691/ph.2007.2.6120
4. Breier AR, Paim CS, Steppe M, Schapoval EES. Development and validation of dissolution test for fexofenadine hydrochloride capsules and coated tablets. J Pharm Pharm Sci. 2005; 8: 289-298. http://www.ncbi.nlm.nih.gov/pubmed/16124939
5. Karakus S, Kucukguzel L, Kucukguzel SG. Development and validation of a RP-HPLC method for the determination of cetirizine or fexofenadine with pseudoephedrine in binary pharmaceutical dosage forms. J Pharm Biomed Anal. 2008; 46: 295-302. http://dx.doi.org/10.1016/j.jpba.2007.10.018
6. Zafar F, Shoaib MH, Yousuf RI. Development of RP-HPLC method for fexofenadine determination in tablet formulations and development of dissolution method. Pak J Pharmacol. 2011; 28: 43-49.
7. Hofmann U, Seiler M, Drescher S, Fromm MF. Determination of fexofenadine in human plasma and urine by liquid chromatography-mass spectrometry. J Chromatogr B. 2002; 766: 227-233. http://dx.doi.org/10.1016/S0378-4347(01)00468-6
8. Flynn CA, Alnouti Y, Reed GA. Quantification of the transporter substrate fexofenadine cell lysates by liquid chromatography/tandem mass spectrometry. Rapid Comm Mass Spectrom. 2011; 25: 2361-2366. http://dx.doi.org/10.1002/rcm.5111
9. Nirogi RV, Kandikere VN, Shukla M, Mudigonda K, Mayurya S, Komarneni P. Simultaneous quantification of fexofenadine and pseudoephedrine in human plasma by liquid chromatography/tandem mass spectrometry with electrospray ionization: method development, validation and application to a clinical study. Rapid Comm Mass Spectrom. 2006; 20: 3030-3038. http://dx.doi.org/10.1002/rcm.2701
10. Miura M, Uno T, Tateishi T, Suzuki T. Determination of fexofenadine enantimers in human plasma with high performance liquid chromatography. J Pharm Biomed Anal. 2007; 43: 741-745. http://dx.doi.org/10.1016/j.jpba.2006.07.033
11. Arayen M S, Sultana N, Shehnaz H, Haider A. RP-HPLC method for the quantitative determination of fexofenadine hydrochloride in coated tablets and human serum. Med Chem Res. 2011; 20: 55-61. http://dx.doi.org/10.1007/s00044-009-9285-6
12. Pathak SM, Kumar AR, Musmade P, Udupa N. A simple and rapid high performance liquid chromatographic method with fluorescence detection for the estimation of fexofenadine in rat plasma-application to preclinical pharmacokinetics. Talanta. 2008; 76: 338-346. http://dx.doi.org/10.1016/j.talanta.2008.02.047
13. Breier AR, Nudelman NS, Steppe M, Schapoval EES. Isolation and structure elucidation of photodegradation products of fexofenadine. J Pharm Biomed Anal. 2008; 46: 250-257. http://dx.doi.org/10.1016/j.jpba.2007.09.017
14. Breier AR, Steppe M, Schapoval EES. Photodegradation Kinetics of Fexofenadine Hydrochloride Using a LC Method. Chromatographia. 2006; 64: 725-729. http://dx.doi.org/10.1365/s10337-006-0096-3
15. Radhakrishna T, Reddy GO. Simultaneous determination of fexofenadine and its related compounds by HPLC. J Pharm Biomed Anal. 2002, 29: 681-690. http://dx.doi.org/10.1016/S0731-7085(02)00181-4
16. Sharaf El-Din MK, Ibrahim F, Eid MI, Wahba MEK. Validated stability-indicating liquid chromatographic method for the determination of fexofenadine hydrochloride in presence of its degradation products. Application to tablets and content uniformity testing. J Pharmacy Res. 2011; 4: 2377-2380.
17. International Conference on Harmonisation. ICH Q1A (R2), Stability Testing of new Drug Substances and Products, 2003.
18. International Conference on Harmonisation. ICH Q2 (R1), Validation of Analytical Procedures: Text and Methodology, 2005.
19. International Conference on Harmonisation. ICH Q1B (R2), Photostability testing on new drug substances and products, 1996.